• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

半乳糖修饰的红细胞膜融合脂质体能够将药物纳米颗粒靶向递送至肝脏。

Galactose-modified erythrocyte membrane fusion liposomes enable the targeted delivery of drug nanoparticles to the liver.

作者信息

Song Jiayu, Zhang Huanhuan, Zhang Xiaohui, Liu Meiying, Peng Dan, Ren Yuan, Sun Yan, Li Yunlan

机构信息

School of Pharmaceutical Science, Shanxi Medical University Taiyuan 030001 P. R. China

College of Medical Technology, Luohe Medical College Luohe 462000 P. R. China.

出版信息

RSC Adv. 2025 May 29;15(22):17781-17794. doi: 10.1039/d4ra07489k. eCollection 2025 May 21.

DOI:10.1039/d4ra07489k
PMID:40443690
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12120831/
Abstract

The safe and efficient delivery of chemicals and biologics remains crucial for liver disease therapy. In this study, we developed a targeted drug delivery system utilizing a galactose-modified erythrocyte membrane coating technique and drug liposome nanoparticles, which were further optimized using orthogonal experiments and response surface analysis. The specificity, precision, accuracy, and stability exhibited satisfactory performance in bioanalytical analysis. Specifically, targeting ligands (Gal-DSPE-PEG3400) were efficiently inserted into red blood cell (RBC) membranes using a facile insertion method. When Gal-DSPE-PEG3400-RBC was fused with fenofibrate liposome nanoparticles (FNB-Lip) by co-extrusion, the resulting galactose-modified erythrocyte membrane fusion liposome nanoparticles (Gal-RBC-FNB-Lip) showed long-term stability, excellent biocompatibility, prolonged retention time, and superior liver accumulation and therapeutic efficacy. These qualities make it suitable for effective drug delivery. The findings of this study will provide a fundamental basis for research and development of liver-targeted drugs and offer novel insights into the treatment of clinical liver diseases.

摘要

化学品和生物制品的安全有效递送对于肝病治疗仍然至关重要。在本研究中，我们开发了一种靶向给药系统，利用半乳糖修饰的红细胞膜包衣技术和药物脂质体纳米颗粒，并通过正交实验和响应面分析对其进行进一步优化。其特异性、精密度、准确度和稳定性在生物分析中表现出令人满意的性能。具体而言，通过一种简便的插入方法将靶向配体（Gal-DSPE-PEG3400）有效地插入红细胞（RBC）膜中。当Gal-DSPE-PEG3400-RBC与非诺贝特脂质体纳米颗粒（FNB-Lip）通过共挤出融合时，所得的半乳糖修饰红细胞膜融合脂质体纳米颗粒（Gal-RBC-FNB-Lip）表现出长期稳定性、优异的生物相容性、延长的保留时间以及卓越的肝脏蓄积和治疗效果。这些特性使其适用于有效的药物递送。本研究结果将为肝靶向药物的研发提供基础依据，并为临床肝病治疗提供新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/52cec43bd6bb/d4ra07489k-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/15bb141346cd/d4ra07489k-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/bf3575cd119a/d4ra07489k-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/012623791225/d4ra07489k-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/c4881e141bf0/d4ra07489k-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/5eb2ae601ef5/d4ra07489k-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/531637f23500/d4ra07489k-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/7b2fd38dc8eb/d4ra07489k-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/52cec43bd6bb/d4ra07489k-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/15bb141346cd/d4ra07489k-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/bf3575cd119a/d4ra07489k-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/012623791225/d4ra07489k-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/c4881e141bf0/d4ra07489k-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/5eb2ae601ef5/d4ra07489k-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/531637f23500/d4ra07489k-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/7b2fd38dc8eb/d4ra07489k-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1688/12120831/52cec43bd6bb/d4ra07489k-f8.jpg

相似文献

1
Galactose-modified erythrocyte membrane fusion liposomes enable the targeted delivery of drug nanoparticles to the liver.半乳糖修饰的红细胞膜融合脂质体能够将药物纳米颗粒靶向递送至肝脏。
RSC Adv. 2025 May 29;15(22):17781-17794. doi: 10.1039/d4ra07489k. eCollection 2025 May 21.
2
Ligand-Modified Cell Membrane Enables the Targeted Delivery of Drug Nanocrystals to Glioma.配体修饰的细胞膜使药物纳米晶体能够靶向递送至神经胶质瘤。
ACS Nano. 2019 May 28;13(5):5591-5601. doi: 10.1021/acsnano.9b00661. Epub 2019 May 13.
3
Dual-targeting galactose-functionalized hyaluronic acid modified lipid nanoparticles delivering silybin for alleviating alcoholic liver injury.双靶向半乳糖化透明质酸修饰脂质纳米粒递送水飞蓟宾用于缓解酒精性肝损伤。
Int J Pharm. 2024 Dec 5;666:124662. doi: 10.1016/j.ijpharm.2024.124662. Epub 2024 Sep 4.
4
Biodistribution of liposomes containing synthetic galactose-terminated diacylglyceryl-poly(ethyleneglycol)s.含有合成半乳糖末端二酰基甘油-聚乙二醇的脂质体的生物分布
Biochim Biophys Acta. 1997 Jun 12;1326(2):329-41. doi: 10.1016/s0005-2736(97)00036-9.
5
Hybrid liposome-erythrocyte drug delivery system for tumor therapy with enhanced targeting and blood circulation.用于肿瘤治疗的具有增强靶向性和血液循环能力的脂质体-红细胞混合药物递送系统。
Regen Biomater. 2023 Apr 26;10:rbad045. doi: 10.1093/rb/rbad045. eCollection 2023.
6
Perspective on the Application of Erythrocyte Liposome-Based Drug Delivery for Infectious Diseases.基于红细胞脂质体的药物递送在传染病治疗中的应用前景
Membranes (Basel). 2022 Dec 3;12(12):1226. doi: 10.3390/membranes12121226.
7
Oriented Assembly of Cell-Mimicking Nanoparticles via a Molecular Affinity Strategy for Targeted Drug Delivery.通过分子亲和策略对细胞模拟纳米粒子进行定向组装，用于靶向药物传递。
ACS Nano. 2019 May 28;13(5):5268-5277. doi: 10.1021/acsnano.8b09681. Epub 2019 Apr 29.
8
Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy.聚亚乙基亚胺和半乳糖修饰的超顺磁性氧化铁纳米颗粒用于肝细胞癌治疗中的 siRNA 靶向递送。
Int J Nanomedicine. 2018 Mar 26;13:1851-1865. doi: 10.2147/IJN.S155537. eCollection 2018.
9
Preparation and in vivo evaluation of red blood cell membrane coated porous silicon nanoparticles implanted with Tb.载钽多孔硅纳米粒的制备及其在体内的评价
Nucl Med Biol. 2020 May-Jun;84-85:102-110. doi: 10.1016/j.nucmedbio.2020.04.001. Epub 2020 Apr 10.
10
Co-Delivery of Curcumin and Capsaicin by Dual-Targeting Liposomes for Inhibition of aHSC-Induced Drug Resistance and Metastasis.双重靶向脂质体共递送姜黄素和辣椒素抑制 aHSC 诱导的耐药性和转移。
ACS Appl Mater Interfaces. 2021 Apr 14;13(14):16019-16035. doi: 10.1021/acsami.0c23137. Epub 2021 Apr 5.

本文引用的文献

1
Sensitize Tumor Immunotherapy: Immunogenic Cell Death Inducing Nanosystems.致敏肿瘤免疫治疗：免疫原性细胞死亡诱导纳米系统。
Int J Nanomedicine. 2024 Jun 13;19:5895-5930. doi: 10.2147/IJN.S457782. eCollection 2024.
2
Nanoparticle-Mediated Synergistic Chemoimmunotherapy for Cancer Treatment.纳米颗粒介导的协同化免疫疗法治疗癌症。
Int J Nanomedicine. 2024 May 21;19:4533-4568. doi: 10.2147/IJN.S455213. eCollection 2024.
3
Targeted Delivery of Gemcitabine for Precision Therapy of Cholangiocarcinoma Using Hyaluronic Acid-Modified Metal-Organic Framework Nanoparticles.
使用透明质酸修饰的金属有机框架纳米颗粒实现吉西他滨的靶向递送用于胆管癌的精准治疗
ACS Omega. 2024 Feb 27;9(10):11998-12005. doi: 10.1021/acsomega.3c09751. eCollection 2024 Mar 12.
4
Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease.肠道微生物群与代谢功能障碍相关脂肪性肝病的代谢生物标志物。
Hepatol Commun. 2024 Feb 26;8(3). doi: 10.1097/HC9.0000000000000310. eCollection 2024 Mar 1.
5
Role of fenofibrate in multiple sclerosis.非诺贝特在多发性硬化症中的作用。
Eur J Med Res. 2024 Feb 9;29(1):113. doi: 10.1186/s40001-024-01700-2.
6
Arbidol attenuates liver fibrosis and activation of hepatic stellate cells by blocking TGF-β1 signaling.阿比朵尔通过阻断转化生长因子-β1信号传导减轻肝纤维化并抑制肝星状细胞激活。
Eur J Pharmacol. 2024 Mar 15;967:176367. doi: 10.1016/j.ejphar.2024.176367. Epub 2024 Feb 6.
7
Molecular characterisation of Entamoeba histolytica UDP-glucose 4-epimerase, an enzyme able to provide building blocks for cyst wall formation.溶组织内阿米巴 UDP-葡萄糖 4-差向异构酶的分子特征，该酶能够提供形成包囊壁的构建块。
PLoS Negl Trop Dis. 2023 Aug 24;17(8):e0011574. doi: 10.1371/journal.pntd.0011574. eCollection 2023 Aug.
8
Hyaluronidase-trigger nanocarriers for targeted delivery of anti-liver cancer compound.用于靶向递送抗肝癌化合物的透明质酸酶触发纳米载体。
RSC Adv. 2023 Apr 11;13(16):11160-11170. doi: 10.1039/d3ra00693j. eCollection 2023 Apr 3.
9
Global burden of liver disease: 2023 update.全球肝病负担：2023 年更新。
J Hepatol. 2023 Aug;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017. Epub 2023 Mar 27.
10
Advanced Phytochemical-Based Nanocarrier Systems for the Treatment of Breast Cancer.用于治疗乳腺癌的先进植物化学基纳米载体系统
Cancers (Basel). 2023 Feb 6;15(4):1023. doi: 10.3390/cancers15041023.